Erschienen in:
01.04.2011 | Letter to the Editor
Exploiting a Physiological Regulator to Improve the Efficacy and Safety of Statins
verfasst von:
Saloni Gill, Andrew J. Brown
Erschienen in:
Cardiovascular Drugs and Therapy
|
Ausgabe 2/2011
Einloggen, um Zugang zu erhalten
Excerpt
Statins are the first choice of therapy to combat raised blood cholesterol levels and cardiovascular disease. Overall, they are comparatively safe but like any other drug, statins are not exempt from adverse reactions [
1]. Importantly, with statin use, dose and potency all on the rise, the number of adverse reactions can be expected to also increase [
2]. This is recognised as an important area of investigation, with numerous trials underway to ameliorate the side-effects of statins (particularly those involving Coenzyme Q and muscle-related side-effects) [
3]. Also, major patents are on the verge of expiring (most notably for Lipitor in 2011), providing added impetus to develop new combination therapies. …